Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Ascendis Pharma A/S ASND

Set alert

Price alert · ASND

All alert types
248.98 USD -2.29 -0.91%

At close · Nov 2

248.98 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
248.82 × 2
Ask
249.02 × 2
248.68 Day range 253.71
196.01 52-week range 277.18
YTD
+16.76%
1 year
+23.50%
Open
252.55
Prev close
251.27
Mkt cap
16.38B
Vol
479.91K
Avg vol
703.07K
EPS
12.93
P/E
19.26
Div yield
0.00%
More statistics
Low
248.68
High
253.71
Forward P/E
24.90
Beta
0.00
Short ratio
3.27
Inst. own
103.67%
Dividend
0.00
Ex-div date
Earnings
Nov 11, 2026
50-d avg
242.31
200-d avg
238.10
1y target
304.67

5D chart

Chart tools
Interval
1m5m15m30m

Signals (122)
NameTimeAgo
SMA: BearishNov 2, 9:30 AM18 hours ago
SMA: BullishOct 30, 3:45 PM3 days ago
SMA: BearishOct 30, 3:40 PM3 days ago
SMA: BullishOct 30, 3:30 PM3 days ago
SMA: BullishOct 30, 3:20 PM3 days ago
SMA: BearishOct 30, 3:15 PM3 days ago
SMA: BullishOct 30, 3:10 PM3 days ago
MACD: Buy SignalOct 30, 3:10 PM3 days ago
RSI: OversoldOct 30, 2:35 PM3 days ago
RSI: OversoldOct 30, 1:50 PM3 days ago
MACD: Sell SignalOct 30, 1:35 PM3 days ago
SMA: BearishOct 30, 1:30 PM3 days ago
SMA: BullishOct 30, 1:20 PM3 days ago
SMA: BearishOct 30, 1:10 PM3 days ago
SMA: BullishOct 30, 1:00 PM3 days ago
MACD: Buy SignalOct 30, 12:55 PM3 days ago
SMA: BearishOct 30, 12:40 PM3 days ago
SMA: BullishOct 30, 12:25 PM3 days ago
SMA: BearishOct 30, 12:15 PM3 days ago
SMA: BearishOct 30, 12:15 PM3 days ago

Newest 20 of 122.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 304.67 +22.4% upside
Target (low)
261.81
Target (mean)
304.67
Target (high)
343.27
Ratings (0m) 22 21 buy · 1 hold · 0 sell
  • Strong buy5
  • Buy16
  • Hold1
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 22
  • 1 month ago 20
  • 2 months ago 20

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ASND analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter1.120.65 – 1.650.000.0%367.14M+71.9%4
Next quarter1.420.60 – 2.230.000.0%414.65M+67.5%4
Current year10.083.61 – 15.620.000.0%1.37B+90.8%5
Next year8.906.26 – 12.5610.08-11.7%2.01B+46.2%5

Upgrades and downgrades

The latest rating changes

ASND analyst upgrades and downgrades
DateFirmActionFromTo
Oct 26, 2026CitigroupMaintainedBuyBuy
Sep 25, 2026Cantor FitzgeraldReiteratedOverweightOverweight
Sep 15, 2026Raymond JamesDowngradeStrong BuyOutperform
Sep 2, 2026OppenheimerMaintainedOutperformOutperform
Sep 1, 2026Morgan StanleyMaintainedOverweightOverweight
Sep 1, 2026WedbushReiteratedOutperformOutperform
Aug 31, 2026B of A SecuritiesMaintainedBuyBuy
Aug 31, 2026JefferiesMaintainedBuyBuy
Aug 31, 2026StifelMaintainedBuyBuy
Aug 31, 2026HC Wainwright & Co.MaintainedBuyBuy
Aug 27, 2026HC Wainwright & Co.Initiated—Buy
Aug 19, 2026BMO CapitalInitiated—Outperform
Aug 14, 2026TD CowenMaintainedBuyBuy
Aug 14, 2026RBC CapitalMaintainedOutperformOutperform
Aug 14, 2026BarclaysMaintainedOverweightOverweight
Jul 23, 2026Morgan StanleyMaintainedOverweightOverweight
Jul 7, 2026RBC CapitalMaintainedOutperformOutperform
May 19, 2026CitigroupInitiated—Buy
May 15, 2026Evercore ISI GroupMaintainedOutperformOutperform
May 11, 2026BarclaysMaintainedOverweightOverweight
May 8, 2026Wells FargoMaintainedOverweightOverweight
Apr 16, 2026B of A SecuritiesMaintainedBuyBuy
Apr 9, 2026WedbushReiteratedOutperformOutperform
Mar 3, 2026RBC CapitalMaintainedOutperformOutperform
Feb 12, 2026OppenheimerMaintainedOutperformOutperform
Feb 12, 2026WedbushMaintainedOutperformOutperform
Jan 30, 2026B of A SecuritiesMaintainedBuyBuy
Jan 28, 2026BarclaysInitiated—Overweight
Jan 20, 2026RBC CapitalMaintainedOutperformOutperform
Jan 20, 2026Wells FargoMaintainedOverweightOverweight